StockWireNews
Nasdaq Low Float Profile (GLMD) Could Earn Breakout Buzz Monday (Here's Why)
March 17th
Greetings Readers,
Drop what you're doing and consider Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD).
GLMD is a past champ. Alerted previously this past August after closing at $.3019, it surged in pre-market the next day all the way to a mind-blowing high of $.8516!
That's a blockbuster run in the form of an approx. 182% move!
Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases.
Their lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.
They are also developing Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.
Learn More Here.
-----
(Nasdaq: GLMD) - 2 Immediate Points Of Interest
#1. GLMD is a low float profile.
With roughly 1.31Mn shares in its float, the chances for heightened volatility on a daily basis could be ever-present.
#2. GLMD has multiple oversold technical indicators.
Barchart is reporting conditions that may signal a reversal could be nearing for GLMD.
A 9-Day and 14-Day Relative Strength Index both below 29% at close on Friday, along with a 14-Day Raw Stochastic of 4.86% and a 14-Day Williams %R of 95.14%, this Nasdaq idea may be viewed as undervalued from current levels.
-----
Coverage is initiated on Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD).
Consider getting it on your watchlist quickly.
Sincerely,
Kai Parker
StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
ليست هناك تعليقات:
إرسال تعليق